Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients

BMC Infectious Diseases

Table 1 In vitro antifungal susceptibilities of 638 clinical yeast isolates determined by CLSI M27-A2, Etest and Sensititre

Drug	Method	MIC values			% of R strains	CA%	% of isolates with discrepant results
		Ranges	50%	90%			Minor	Major	Very major
	CLSI	0.12-2	0.5	1	2.6
Amphotericin B	Etest	0.032-8	0.19	0.38	0.2	97.5	-	-	2.5
	Sensititre	0.03-2	0.5	1	0.4	97.3	-	0.2	2.5
	CLSI	<0.008-≥16	0.12	16	3.6
Anidulafungin	Etest	≤0.002-≥32	0.008	1.5	3.8	94.7	-	2.1	3.2
	Sensititre	≤0.008-≥16	0.06	1	1.7	96.4	-	-	3.6
	CLSI	0.016-≥16	1	2	6.7
Caspofungin	Etest	0.012-≥32	0.19	0.75	2.2	95.0	-	0.2	4.8
	Sensititre	0.015-≥16	0.12	0.5	2.2	95.3	-	-	4.7
	CLSI	≤0.12-128	0.5	16	3.3
Fluconazole	Etest	0.032-≥256	0.38	8	2.2	91.1	7.7	0.2	1
	Sensititre	≤0.12-≥256	0.5	16	2.7	89.8	0.2	0.2	9.8
Itraconazole	CLSI	0.008-≥16	0.25	1	7.8
	Etest	0.004-≥32	0.064	1.5	8.9	47.7	49.2	-	3.1
	Sensititre	≤0.008-≥8	0.03	1	5.9	46.8	59.2	-	4.0
Posaconazole	CLSI	≤0.008-≥8	0.12	1	6.5
	Etest	0.003-≥32	0.064	0.5	10.6	93.4	4.8	1.6	0.2
	Sensititre	≤0.008-≥8	0.03	1	2.3	96.0	3.5	-	0.5
Voriconazole	CLSI	≤0.008-8	0.016	0.25	1.9
	Etest	≤0.002-≥32	0.023	0.25	1.4	98.8	0.9	-	0.3
	Sensititre	≤0.008-8	0.008	0.25	1.1	98.3	1.0	0.2	0.5

* Categorical Agreement (MIC values that fell within the same interpretive categories)

ISSN: 1471-2334